548.     Zhang XD, Wu JJ, Gillespie S, Borrow JM, Hersey P. Cross resistance of melanoma to TRIAL induced apoptosis and chemotherapy. In: Giaccone G, Schilsky R, Sondel P, eds. Cancer Chemotherapy and Biological Response Modifiers. New York: Elsevier; 2005.

547.     Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, McCarthy WH, O'Brien CJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Uren RF. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 2005;12:429-39.

546.     Wu JJ, Zhang XD, Gillespie S, Hersey P. Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Lett 2005;579:1940-4.

545.     van Poll D, Thompson JF, Colman MH, McKinnon JG, Saw RP, Stretch JR, Scolyer RA, Uren RF. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:597-608.

544.     Thompson JF, Uren RF, Saw RP, Stevens GN. Internal mammary node metastasis from primary cutaneous melanoma on the anterior chest. ANZ J Surg 2005;75:723-5.

543.     Thompson JF, Shaw HM. Who should treat patients with primary melanoma? Br J Dermatol 2005;153:459-60; author reply 8-9.

542.     Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.

541.     Starritt EC, Uren RF, Scolyer RA, Quinn MJ, Thompson JF. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:18-23.

540.     Scolyer RA, Thompson JF. Desmoplastic melanoma: a heterogeneous entity in which subclassification as "pure" or "mixed" may have important prognostic significance. Ann Surg Oncol 2005;12:197-9.

539.     Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005;23:4588-90.

538.     Pawlik TM, Ross MI, Shaw HM, Thompson JF, Gershenwald JE. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol 2005;31:323-4.

537.     Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-11; discussion 11-3.

536.     Millward MJ, Joshua A, Kefford R, Aamdal S, Thomson D, Hersey P, Toner G, Lynch K. Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest New Drugs 2005;23:253-6.

535.     McKinnon JG, Starritt EC, Scolyer RA, McCarthy WH, Thompson JF. Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. Ann Surg 2005;241:326-33.

534.     Mansberg R, Crawford B, Uren RF, Thompson JF. Minimally Invasive Radio-Guided Surgery for Recurrent Thyroid Cancer Using Iodine-123. Clin Nucl Med 2005;30:43-4.

533.     Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunology, Immunotherapy 2005;54:208-18.

532.     Gillespie SK, Zhang XD, Hersey P. Ingenol 3-angelate induces dual modes of cell death and differentially regulates TRIAL-induced apoptosis in melanoma cells. Mol Cancer Ther 2005;3:668-76.

531.     Gillespie S, Zhang XD, Hersey P. Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Mol Cancer Ther 2005;4:668-76.

530.     Francken AB, Hong AM, Fulham MJ, Millward MJ, McCarthy WH, Thompson JF. Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography. Eur J Surg Oncol 2005;31:197-204.

529.     Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, McCarthy WH. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research 2005;15:45-51.

528.     Bourne RM, Stanwell P, Stretch JR, Scolyer RA, Thompson JF, Mountford CE, Lean CL. In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. Eur J Radiol 2005;53:506-13.

527.     Becker TM, Rizos H, de la Pena A, Leclercq IA, Woodruff S, Kefford RF, Mann GJ. Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochem Biophys Res Commun 2005;332:873-9.

526.     Becker TM, Ayub AL, Kefford RF, Mann GJ, Rizos H. The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. Int J Cancer 2005;117:569-73.

525.     Allen JD, Zhang XD, Scott CL, Boyle GM, Hersey P, Strasser A. Is Apaf-1 expression frequently abrogated in melanoma? Cell Death Differ 2005;12:680-1.